Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
VBI Vaccines Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VBIV
Nasdaq
8731
https://www.vbivaccines.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for VBI Vaccines Inc
VBI Vaccines Reports Full Year 2023 Financial Results
- Apr 16th, 2024 12:00 pm
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Apr 11th, 2024 8:05 pm
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Apr 9th, 2024 6:45 pm
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
- Apr 3rd, 2024 12:00 pm
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
- Apr 2nd, 2024 12:00 pm
Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
- Feb 14th, 2024 5:48 pm
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
- Feb 14th, 2024 12:00 pm
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
- Nov 20th, 2023 1:00 pm
VBI Vaccines Reports Third Quarter 2023 Financial Results
- Nov 14th, 2023 9:05 pm
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
- Oct 26th, 2023 12:00 pm
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
- Sep 27th, 2023 11:30 am
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
- Sep 7th, 2023 12:00 pm
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
- Sep 6th, 2023 12:00 pm
VBI Vaccines Reports Second Quarter 2023 Financial Results
- Aug 14th, 2023 12:00 pm
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
- Aug 3rd, 2023 10:25 pm
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
- Jul 24th, 2023 12:00 pm
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
- Jul 19th, 2023 12:00 pm
7 Biotech Stocks to Sell in July
- Jul 13th, 2023 11:00 am
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
- Jul 6th, 2023 1:00 pm
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
- Jul 5th, 2023 8:12 pm
Scroll